is unaffected by the recommendation GSK also has a five-in-one meningococcal vaccine candidate, which combines the antigenic components of Menveo and its approved meningococcal group B vaccine Bexsero ...

iTeos Therapeutics (NASDAQ:ITOS) announced Saturday that its experimental cancer doublet therapy developed with GSK (NYSE:GSK) outperformed the British drugmaker’s FDA-approved anti-PD-1 therapy ...

In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final analysis of a phase 3 trial. Another study showed that pharma&’s ...

GSK Plc’s experimental vaccine for herpes failed in an early-stage trial, halting an effort to bring the first shot for the condition to market. While there were no safety concerns, the trial ...

After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all ...

Sept 11 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial ...

BARCELONA, Spain — A targeted immunotherapy being developed by the biotech iTeos Therapeutics and GSK delivered promising response rates in patients with a type of lung cancer, propelling the ...

However, the earlier flops shook TIGIT players, with GSK and iTeos assessing “how best to proceed with additional clinical development” of their rival asset after a phase 3 Roche flop in 2022 ...

GSK has demonstrated robust sales growth, with a 13% increase to GBP 7.9 billion and a core operating profit up by 21% to GBP 2.5 billion, as noted by CEO Emma Walmsley in the latest earnings call.

As part of the agreement, GSK, Sanofi, and CSL will produce extra bulk vaccine components tailored to the circulating strains of avian influenza. Also Read: Medicare Drug Price Negotiation Program ...

GSK’s (NYSE:GSK) investigational herpes simplex virus (HSV) vaccine candidate failed to meet the primary goal of a mid-stage trial and will not progress to a late-stage trial. The British ...